Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double ...

The previous Paralympic logo incorporated the Tae-Geuk, which is a traditional Korean decorative motif. According to oriental philosophy, Tae-Geuk refers to the ultimate reality from which all things ...

Chris Rose of ProStrakan offers advice on selling in the pharmaceutical industry. The 80's and 90's spawned a host of selling models and most of us in the pharma business have been trained to use ...

When it comes to claiming market control, pharmaceutical companies stand apart from healthcare’s other monopolies. Whereas hospitals and health systems rely primarily on mergers and acquisitions ...

The global pharmaceutical industry is growing and offers an attractive opportunity for investors. Well-established pharmaceutical stocks include AbbVie, Eli Lilly, Johnson & Johnson, and Pfizer.

SAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. BioMarin ...

What is Pharma 4.0? The term Industry 4.0 refers to the fourth industrial revolution, associated with the application of advanced technologies that have dramatically changed the landscape of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A good imagination and persistence are required. Medicinal and pharmaceutical chemists apply their chemistry training to the process of synthesizing new pharmaceuticals. They also improve the ...

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.